Contact
Subscribe

Category

December 8, 2025

[article_filters]
Website_maat_logo

December 8, 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

MaaT Pharma
December 8, 2025

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

MaaT Pharma in the News